Cargando…

Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis

Hypertrophic cardiomyopathy (HCM) is a clinically and genetically heterogeneous disorder but data on survival rates are still conflicting and have not so far been quantitatively reviewed. The aim of this study is to conduct a meta-analysis of cohort studies to assess pooled survival rates and progno...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qun, Li, Diandian, Berger, Alan E., Johns, Roger A., Gao, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607340/
https://www.ncbi.nlm.nih.gov/pubmed/28931939
http://dx.doi.org/10.1038/s41598-017-12289-4
_version_ 1783265278930452480
author Liu, Qun
Li, Diandian
Berger, Alan E.
Johns, Roger A.
Gao, Li
author_facet Liu, Qun
Li, Diandian
Berger, Alan E.
Johns, Roger A.
Gao, Li
author_sort Liu, Qun
collection PubMed
description Hypertrophic cardiomyopathy (HCM) is a clinically and genetically heterogeneous disorder but data on survival rates are still conflicting and have not so far been quantitatively reviewed. The aim of this study is to conduct a meta-analysis of cohort studies to assess pooled survival rates and prognostic factors for survival in patients with HCM. Nineteen studies were included representing 12,146 HCM patients. The pooled 1-, 3-, 5- and 10-year survival rates were 98.0%, 94.3%, 82.2% and 75.0%, respectively. Among patients with HCM, age, NYHA functional class, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickness and obstruction were significant prognostic factors for cardiovascular death. For sudden cardiac death, FHSD, nsVT, and obstruction showed significant predictive values. Moreover, estimation of population attributable risk (PAR) suggested that nsVT was the strongest predictor for cardiovascular death (13.02%, 95% CI 3.60–25.91%), while left ventricular outflow tract obstruction/mid-ventricular obstruction (LVO/MVO) was the strongest predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72–20.42% and 16.44%, 95% CI 7.45–31.55%, respectively). These risk factors may thus be useful for identifying HCM patients who might benefit from early diagnosis and therapeutic interventions.
format Online
Article
Text
id pubmed-5607340
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56073402017-09-24 Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis Liu, Qun Li, Diandian Berger, Alan E. Johns, Roger A. Gao, Li Sci Rep Article Hypertrophic cardiomyopathy (HCM) is a clinically and genetically heterogeneous disorder but data on survival rates are still conflicting and have not so far been quantitatively reviewed. The aim of this study is to conduct a meta-analysis of cohort studies to assess pooled survival rates and prognostic factors for survival in patients with HCM. Nineteen studies were included representing 12,146 HCM patients. The pooled 1-, 3-, 5- and 10-year survival rates were 98.0%, 94.3%, 82.2% and 75.0%, respectively. Among patients with HCM, age, NYHA functional class, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickness and obstruction were significant prognostic factors for cardiovascular death. For sudden cardiac death, FHSD, nsVT, and obstruction showed significant predictive values. Moreover, estimation of population attributable risk (PAR) suggested that nsVT was the strongest predictor for cardiovascular death (13.02%, 95% CI 3.60–25.91%), while left ventricular outflow tract obstruction/mid-ventricular obstruction (LVO/MVO) was the strongest predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72–20.42% and 16.44%, 95% CI 7.45–31.55%, respectively). These risk factors may thus be useful for identifying HCM patients who might benefit from early diagnosis and therapeutic interventions. Nature Publishing Group UK 2017-09-20 /pmc/articles/PMC5607340/ /pubmed/28931939 http://dx.doi.org/10.1038/s41598-017-12289-4 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Qun
Li, Diandian
Berger, Alan E.
Johns, Roger A.
Gao, Li
Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
title Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
title_full Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
title_fullStr Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
title_full_unstemmed Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
title_short Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
title_sort survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607340/
https://www.ncbi.nlm.nih.gov/pubmed/28931939
http://dx.doi.org/10.1038/s41598-017-12289-4
work_keys_str_mv AT liuqun survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis
AT lidiandian survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis
AT bergeralane survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis
AT johnsrogera survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis
AT gaoli survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis